Ranibizumab for the Inhibition of Neovascularization in Pterygia

Part of paid clinical trials in Miami, Florida.

Sponsor: University of Miami
Study ID: NCT00768963
Phase: PHASE1
Status: Completed

Conditions

Pterygium

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

ranibizumab — DRUG
0.5 mg subconjunctival ranibizumab 3 days prior to surgery
ranibizumab — DRUG
0.5 mg subconjunctival ranibizumab at the time of surgery

Study Details

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Key Dates

First listed: Oct 8, 2008
Start date: Oct 31, 2008
Status verified: Jul 2017
Primary completion: Nov 30, 2011
Completion: Jan 31, 2012

Study Design

Enrollment: 10 participants (actual)
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: 1
Patients will receive one injection of ranibizumab 3 days prior to surgery
Experimental: 2
Patients will undergo one injection of ranibizumab at the time of surgery

Primary Outcome Measure

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery. [ Time Frame: 2 years ]

Locations (1)

Facility	City	State	ZIP	Site coordinators
Bascom Palmer Eye Institute	Miami	Florida	33136	-

Find similar trials in Miami, FL

By research site

Bascom Palmer Eye Institute· Miami, FL